Alnylam Pharmaceuticals
Business Account Executive, Luma: East- Gulf Coast (Finance)
EAST: Gulf Coast
(Includes New Orleans, LA; Birmingham, AL; Nashville, TN)
Overview
Alnylam is the world's leading RNA interference (RNAi) company.
Founded in 2002, Alnylam was built upon a bold vision of turning scientific possibility into reality by harnessing the power of RNAi for human health as an innovative new class of medicines. We are a growing biopharmaceutical company with two approved medicines and a robust pipeline of investigational medicines focused in four strategic therapeutic areas: genetic medicines, cardio-metabolic diseases, infectious diseases, and central nervous system (CNS) and ocular diseases, including several in late-stage development.
Headquartered in Cambridge, Mass., Alnylam employs over 1,400 people in 19 countries and is rapidly growing globally, with additional offices in Norton, Mass., Maidenhead, U.K., Zug, Switzerland, Amsterdam, Netherlands, and Tokyo, Japan. Alnylam is proud to have been recognized as one of The Boston Globe's Top Places to Work five years in a row (2015-2019), a Great Place to Work in the U.K. and Switzerland in 2020 and Science Magazine's #1 Top Employer in 2019. Please visit www.alnylam.com for more information.
We are looking for field-based Business Account Executives (BAEs) with rare/ultra-rare disease expertise to strategically drive the commercial objectives and launch success of the novel RNAi therapy "Lumasiran" for the treatment of Primary Hyperoxaluria Type One (PH1) in the U.S.
Lumasiran (ALN-GO1) is an investigational, subcutaneously administered (under the skin) RNA interference (RNAi) therapeutic targeting glycolate oxidase (GO) in development for the treatment of primary hyperoxaluria type 1 (PH1). PH1 is a rare, life-threatening disease that can cause serious damage to kidneys and progressively to other organs. PH1 is a little-known condition and patients often spend years undiagnosed and misdiagnosed. There is an amazing opportunity to educate and enhance the market's knowledge of PH1.
The BAE is expected to develop territory specific strategic account plans in the context of the overall product strategy and in close alignment and collaboration with functions of Medical Affairs, Clinical Research, Patient Advocacy, Market Access and Commercial, while ensuring full compliance with all relevant company, industry, legal, regulatory and ethical standards.
The Lumasiran BAE will be responsible for driving physician and patient identification, advancing disease awareness, market development, and brand awareness within their assigned territory. The BAE will also act as a strategic partner with PH1 Key Opinion Leaders by gathering and sharing insights to develop advocacy aligned with Alnylam's strategic imperatives and advance our commercial impact. The achievement of objectives will be grounded in Alnylam values: our commitment to people, sense of urgency, passion for excellence, innovation & discovery, open culture as well as our unwavering commitment to integrity. The position reports to the Lumasiran Regional Business Director.
Summary of Key Responsibilities:
Qualifications:
Expectations:
Clear Alignment with Alnylam Core Values